NASDAQ:MIST

Milestone Pharmaceuticals Competitors

$5.40
+0.11 (+2.08 %)
(As of 04/14/2021 04:30 PM ET)
Add
Compare
Today's Range
$5.30
Now: $5.40
$5.52
50-Day Range
$5.35
MA: $6.67
$7.80
52-Week Range
$2.05
Now: $5.40
$11.40
Volume108,223 shs
Average Volume107,029 shs
Market Capitalization$161.17 million
P/E RatioN/A
Dividend YieldN/A
Beta4.2

Competitors

Milestone Pharmaceuticals (NASDAQ:MIST) Vs. ALBO, KDMN, KALV, RLMD, KDNY, and IDYA

Should you be buying MIST stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Milestone Pharmaceuticals, including Albireo Pharma (ALBO), Kadmon (KDMN), KalVista Pharmaceuticals (KALV), Relmada Therapeutics (RLMD), Chinook Therapeutics (KDNY), and IDEAYA Biosciences (IDYA).

Milestone Pharmaceuticals (NASDAQ:MIST) and Albireo Pharma (NASDAQ:ALBO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Risk & Volatility

Milestone Pharmaceuticals has a beta of 4.2, suggesting that its stock price is 320% more volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500.

Valuation & Earnings

This table compares Milestone Pharmaceuticals and Albireo Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone PharmaceuticalsN/AN/A$-55,230,000.00($3.50)-1.54
Albireo Pharma$9.64 million64.22$-62,720,000.00($5.04)-6.43

Milestone Pharmaceuticals has higher earnings, but lower revenue than Albireo Pharma. Albireo Pharma is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Milestone Pharmaceuticals and Albireo Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Milestone PharmaceuticalsN/A-58.89%-55.37%
Albireo Pharma-751.53%-71.22%-42.91%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Milestone Pharmaceuticals and Albireo Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Milestone Pharmaceuticals01402.80
Albireo Pharma00803.00

Milestone Pharmaceuticals presently has a consensus target price of $14.60, indicating a potential upside of 167.89%. Albireo Pharma has a consensus target price of $72.00, indicating a potential upside of 122.57%. Given Milestone Pharmaceuticals' higher possible upside, equities analysts clearly believe Milestone Pharmaceuticals is more favorable than Albireo Pharma.

Insider and Institutional Ownership

51.9% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 85.7% of Albireo Pharma shares are held by institutional investors. 4.2% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Albireo Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Milestone Pharmaceuticals beats Albireo Pharma on 7 of the 13 factors compared between the two stocks.

Milestone Pharmaceuticals (NASDAQ:MIST) and Kadmon (NASDAQ:KDMN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Risk & Volatility

Milestone Pharmaceuticals has a beta of 4.2, suggesting that its stock price is 320% more volatile than the S&P 500. Comparatively, Kadmon has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500.

Valuation & Earnings

This table compares Milestone Pharmaceuticals and Kadmon's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone PharmaceuticalsN/AN/A$-55,230,000.00($3.50)-1.54
Kadmon$5.09 million131.65$-61,370,000.00($0.74)-5.27

Milestone Pharmaceuticals has higher earnings, but lower revenue than Kadmon. Kadmon is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Milestone Pharmaceuticals and Kadmon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Milestone PharmaceuticalsN/A-58.89%-55.37%
Kadmon-768.36%-85.07%-46.46%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Milestone Pharmaceuticals and Kadmon, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Milestone Pharmaceuticals01402.80
Kadmon00503.00

Milestone Pharmaceuticals presently has a consensus target price of $14.60, indicating a potential upside of 167.89%. Kadmon has a consensus target price of $12.75, indicating a potential upside of 228.61%. Given Kadmon's stronger consensus rating and higher possible upside, analysts clearly believe Kadmon is more favorable than Milestone Pharmaceuticals.

Insider and Institutional Ownership

51.9% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 94.8% of Kadmon shares are held by institutional investors. 4.2% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 3.0% of Kadmon shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Kadmon beats Milestone Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Milestone Pharmaceuticals (NASDAQ:MIST) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Risk & Volatility

Milestone Pharmaceuticals has a beta of 4.2, suggesting that its stock price is 320% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500.

Valuation & Earnings

This table compares Milestone Pharmaceuticals and KalVista Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone PharmaceuticalsN/AN/A$-55,230,000.00($3.50)-1.54
KalVista Pharmaceuticals$12.69 million47.73$-29,120,000.00($1.64)-15.20

KalVista Pharmaceuticals has higher revenue and earnings than Milestone Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Milestone Pharmaceuticals and KalVista Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Milestone PharmaceuticalsN/A-58.89%-55.37%
KalVista Pharmaceuticals-229.45%-47.45%-41.84%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Milestone Pharmaceuticals and KalVista Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Milestone Pharmaceuticals01402.80
KalVista Pharmaceuticals00603.00

Milestone Pharmaceuticals presently has a consensus target price of $14.60, indicating a potential upside of 167.89%. KalVista Pharmaceuticals has a consensus target price of $50.1667, indicating a potential upside of 100.99%. Given Milestone Pharmaceuticals' higher possible upside, equities analysts clearly believe Milestone Pharmaceuticals is more favorable than KalVista Pharmaceuticals.

Insider and Institutional Ownership

51.9% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 90.2% of KalVista Pharmaceuticals shares are held by institutional investors. 4.2% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 18.0% of KalVista Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

KalVista Pharmaceuticals beats Milestone Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Milestone Pharmaceuticals (NASDAQ:MIST) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Risk & Volatility

Milestone Pharmaceuticals has a beta of 4.2, suggesting that its stock price is 320% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Profitability

This table compares Milestone Pharmaceuticals and Relmada Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Milestone PharmaceuticalsN/A-58.89%-55.37%
Relmada TherapeuticsN/A-32.03%-31.41%

Valuation & Earnings

This table compares Milestone Pharmaceuticals and Relmada Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone PharmaceuticalsN/AN/A$-55,230,000.00($3.50)-1.54
Relmada TherapeuticsN/AN/AN/A($2.16)-17.02

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Milestone Pharmaceuticals and Relmada Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Milestone Pharmaceuticals01402.80
Relmada Therapeutics01202.67

Milestone Pharmaceuticals presently has a consensus target price of $14.60, indicating a potential upside of 167.89%. Relmada Therapeutics has a consensus target price of $63.3333, indicating a potential upside of 72.24%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Milestone Pharmaceuticals is more favorable than Relmada Therapeutics.

Insider and Institutional Ownership

51.9% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 64.3% of Relmada Therapeutics shares are held by institutional investors. 4.2% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 9.3% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Milestone Pharmaceuticals (NASDAQ:MIST) and Chinook Therapeutics (NASDAQ:KDNY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.

Risk and Volatility

Milestone Pharmaceuticals has a beta of 4.2, meaning that its share price is 320% more volatile than the S&P 500. Comparatively, Chinook Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500.

Profitability

This table compares Milestone Pharmaceuticals and Chinook Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Milestone PharmaceuticalsN/A-58.89%-55.37%
Chinook Therapeutics-215.80%-112.72%-21.36%

Earnings & Valuation

This table compares Milestone Pharmaceuticals and Chinook Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone PharmaceuticalsN/AN/A$-55,230,000.00($3.50)-1.54
Chinook Therapeutics$17.26 million33.88$-82,370,000.00($5.15)-2.68

Milestone Pharmaceuticals has higher earnings, but lower revenue than Chinook Therapeutics. Chinook Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Milestone Pharmaceuticals and Chinook Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Milestone Pharmaceuticals01402.80
Chinook Therapeutics00803.00

Milestone Pharmaceuticals currently has a consensus price target of $14.60, suggesting a potential upside of 167.89%. Chinook Therapeutics has a consensus price target of $30.3333, suggesting a potential upside of 119.97%. Given Milestone Pharmaceuticals' higher probable upside, equities analysts plainly believe Milestone Pharmaceuticals is more favorable than Chinook Therapeutics.

Insider & Institutional Ownership

51.9% of Milestone Pharmaceuticals shares are held by institutional investors. 4.2% of Milestone Pharmaceuticals shares are held by company insiders. Comparatively, 5.9% of Chinook Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Milestone Pharmaceuticals beats Chinook Therapeutics on 8 of the 13 factors compared between the two stocks.

Milestone Pharmaceuticals (NASDAQ:MIST) and IDEAYA Biosciences (NASDAQ:IDYA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.

Risk and Volatility

Milestone Pharmaceuticals has a beta of 4.2, meaning that its share price is 320% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500.

Profitability

This table compares Milestone Pharmaceuticals and IDEAYA Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Milestone PharmaceuticalsN/A-58.89%-55.37%
IDEAYA BiosciencesN/A-28.83%-22.92%

Earnings & Valuation

This table compares Milestone Pharmaceuticals and IDEAYA Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Milestone PharmaceuticalsN/AN/A$-55,230,000.00($3.50)-1.54
IDEAYA BiosciencesN/AN/A$-41,970,000.00($3.36)-5.59

IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Milestone Pharmaceuticals and IDEAYA Biosciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Milestone Pharmaceuticals01402.80
IDEAYA Biosciences00603.00

Milestone Pharmaceuticals currently has a consensus price target of $14.60, suggesting a potential upside of 167.89%. IDEAYA Biosciences has a consensus price target of $29.1250, suggesting a potential upside of 55.33%. Given Milestone Pharmaceuticals' higher probable upside, equities analysts plainly believe Milestone Pharmaceuticals is more favorable than IDEAYA Biosciences.

Insider & Institutional Ownership

51.9% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 62.3% of IDEAYA Biosciences shares are held by institutional investors. 4.2% of Milestone Pharmaceuticals shares are held by company insiders. Comparatively, 20.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

IDEAYA Biosciences beats Milestone Pharmaceuticals on 8 of the 11 factors compared between the two stocks.


Milestone Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.39+0.6%$622.54 million$9.64 million-5.28News Coverage
Gap Down
Kadmon logo
KDMN
Kadmon
1.8$3.90+7.2%$621.98 million$5.09 million-6.50Analyst Downgrade
News Coverage
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$24.92+4.9%$605.76 million$12.69 million-11.98Increase in Short Interest
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$36.77+2.2%$602.22 millionN/A-17.02
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$13.80+0.8%$589.46 million$17.26 million-3.83Analyst Revision
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.79+3.6%$584.23 millionN/A-9.99Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.27+3.6%$561.28 million$8 million-7.85
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$43.37+2.9%$556.83 million$195.89 million123.92
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.64+3.4%$547.56 millionN/A-5.42Gap Down
Inventiva logo
IVA
Inventiva
0.0$13.60+2.9%$540.43 millionN/A0.00News Coverage
Gap Up
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$6.99+0.6%$539.54 million$26.74 million17.48
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$11.75+3.3%$536.73 millionN/A-9.11Increase in Short Interest
News Coverage
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24+0.0%$531.75 millionN/A-3.15News Coverage
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.42+2.4%$529.13 million$1.19 million-6.84
IVERIC bio logo
ISEE
IVERIC bio
1.5$6.01+4.0%$520.28 millionN/A-4.77
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.98+2.6%$519.55 millionN/A-5.63
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$14.80+4.3%$517.94 millionN/A-4.27
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.15+0.5%$516.80 million$25 million-18.69Analyst Report
Evolus logo
EOLS
Evolus
1.3$11.72+0.5%$509.93 million$34.92 million-5.77Analyst Report
Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.3$8.78+2.7%$499.29 million$59.22 million43.90
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.89+1.2%$492.23 million$58.12 million-16.15Decrease in Short Interest
Provention Bio logo
PRVB
Provention Bio
1.6$8.13+4.6%$491.79 millionN/A-5.46Analyst Report
Increase in Short Interest
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$36.38+4.8%$491.46 million$40,000.00-1.58Gap Down
XBiotech logo
XBIT
XBiotech
1.0$16.89+1.2%$491.38 millionN/A1.17
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.22+0.8%$490.51 million$49.65 million-1.72Analyst Upgrade
Akouos logo
AKUS
Akouos
1.6$14.36+1.3%$487.82 millionN/A0.00News Coverage
Gap Down
AC Immune logo
ACIU
AC Immune
1.3$6.87+2.9%$479.82 million$111.75 million-7.63Gap Down
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.91+7.7%$479.67 millionN/A-8.23Gap Down
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.20+0.2%$476.23 millionN/A-2.49
Altimmune logo
ALT
Altimmune
1.9$12.95+2.2%$470.69 million$5.80 million-6.51Increase in Short Interest
89bio logo
ETNB
89bio
1.6$23.78+1.1%$468.93 millionN/A-4.71
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$9.38+0.2%$468.29 million$72.96 million-3.04Analyst Report
News Coverage
Gap Down
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$4.34+13.6%$467.89 million$36.63 million-5.11News Coverage
Gap Up
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$3.12+2.9%$465.11 million$335 million-1.05
Verastem logo
VSTM
Verastem
1.3$2.68+0.7%$463.50 million$17.46 million-1.90Analyst Revision
BCEL
Atreca
1.7$12.42+6.4%$457.44 millionN/A-4.40News Coverage
Gap Down
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.98+0.7%$455.80 million$109.33 million-2.19Analyst Report
Gap Down
Geron logo
GERN
Geron
1.4$1.51+5.3%$455.50 million$460,000.00-4.31Decrease in Short Interest
News Coverage
Gap Down
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.46+1.8%$454.75 million$102.31 million6.66Increase in Short Interest
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$11.94+2.3%$449.54 millionN/A0.00News Coverage
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$18.89+1.1%$447.93 millionN/A0.00News Coverage
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.56+3.2%$446.09 million$56.50 million0.00
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$6.00+1.7%$444.80 millionN/A-12.24
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.22+5.4%$442.48 million$57.49 million-6.07Increase in Short Interest
Gap Down
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.25+4.6%$441.13 million$22.27 million-4.04Insider Buying
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.21+0.7%$440.71 million$6.07 million-3.45News Coverage
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$3.98+2.0%$438.26 million$6.68 million-4.80News Coverage
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$16.61+1.0%$432.01 millionN/A-3.49Gap Down
XOMA logo
XOMA
XOMA
1.3$37.20+0.9%$422.33 million$18.37 million-33.51Increase in Short Interest
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.9$33.70+2.0%$408.42 million$206.55 million-16.93Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.